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Abstract
Sarcomas constitute less than 1% of all cervical malignancies. With over 150 reported cases,
rhabdomyosarcomas represent the most commonly reported sarcoma at this location. In this
report, a select group of the more uncommon sarcomas of the uterine cervix are reviewed,
including all previously reported examples of leiomyosarcoma, liposarcoma, alveolar soft part
sarcoma, Ewing sarcoma/primitive neuroectodermal tumor, undifferentiated endocervical sarcoma,
and malignant peripheral nerve sheath tumor (MPNST). Emphasis is placed on any distinctive
clinicopathologic features of these entities at this unusual location.
Background
In 2004, an estimated 10,520 new malignancies of the
uterine cervix were diagnosed in the United States [1].
There are no current, systematically collected data on the
precise percentage of these cases that were pure sarcomas.
However, during a 5-year period in the United States
(1973–1977), sarcomas constituted only 0.55% of all
malignancies that were reported in the cervix [2]. Based on
current data from individual institutions, and in the
author's own experience, this proportion has remained
largely unchanged. Wright et al [3] identified only 3 pure
sarcomas out of 1583 cervical malignancies treated
between 1986 and 2003 at a large tertiary center in the
United States. [3]. The ratio of benign to malignant mes-
enchymal tumors at this anatomic location is approxi-
mately 1.9:1 [4]. Of the sarcomas, rhabdomyosarcomas,
most commonly of the embryonal subtype, are the most
frequently reported, with over 150 cases in the literature
[4]. The proportional distribution of all previously
reported cases of cervical sarcoma are summarized in fig-
ure 1. In this report, a select group of the more uncom-
mon sarcomas of the uterine cervix are briefly reviewed,
including all previously reported examples of leiomyosar-
coma, liposarcoma, alveolar soft part sarcoma, Ewing sar-
coma, undifferentiated endocervical sarcoma, and
malignant peripheral nerve sheath tumor (MPNST). Since
the basic pathologic features of most of these entities have
been outlined in detail elsewhere in the soft tissue context
[5], the emphasis is placed herein on any distinctive clin-
icopathologic features relating to the uterine cervix.
1. Leiomyosarcoma
Since cervical involvement by uterine corpus leiomyosar-
comas are not uncommon, the diagnosis of a primary cer-
vical leiomyosarcoma requires, at minimum, an attempt
to exclude the possibility that the putative cervical tumor
arose from the corporal isthmus (lower uterine segment).
In the author's opinion, deference should be given to a
corpus location in cases that are truly equivocal. However,
reported examples of cervical leiomyosarcomas that
developed in the cervical stump after supracervical hyster-
ectomies provide sufficient evidence that leiomyosarco-
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mas may indeed arise from this site [6,7] Approximately
30 cervical leiomyosarcomas have been reported [3,6-27].
They generally occur in the perimenopausal and postmen-
opausal population in their 4th to 6th decades of life. How-
ever, one distinctive case has been described in a pediatric
patient [21]. Patients with cervical leiomyosarcomas most
commonly present with abnormal vaginal bleeding and/
or abdominopelvic pain. Macroscopically, the tumors are
typically large (up to 12 cm in one series [9]), poorly cir-
cumscribed masses that either protrude from the cervical
canal or thicken and expand it circumferentially [9].
Microscopically, they display a spectrum of morphologic
subtypes similar to that seen in their corpus counterparts,
including the myxoid variant [17], epithelioid variant
[3,8,12,13,15], cases with an abundance of xanthomatous
cells [16] and of course, conventional types. Furthermore,
we have previously indicated [4] that we consider the
"mesenchymal sarcoma", reported by Bader and Rundle
[27] a probable example of leiomyosarcoma with osteo-
clast-like giant cells, another morphologic variation. The
latter – osteoclast-like giant cells – are now well-recog-
nized to occasionally occur in both endometrial stromal
and smooth muscle tumors of the uterus [28,29]. An
insufficient number of cervical leiomyosarcomas have
been reported to devise the kind of elaborate morphologic
criteria that are in routine use for uterine smooth muscle
tumors. The current approach is to simply extrapolate
diagnostic criteria from the corpus tumors and apply
them to their cervical counterparts, incorporating various
combinations of cytologic atypia, coagulative necrosis
Proportional distribution (estimated) of all previously reported cases of cervical sarcoma Figure 1
Proportional distribution (estimated) of all previously reported cases of cervical sarcoma.
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and mitotic activity to predict their malignant potential
[4]. However, it is unclear if this is entirely appropriate in
all cases [30].
Since therapeutic measures have been widely discordant
amongst the reported cases, their true natural history and
any variations in their malignant potential are not readily
evaluable. In a 1983 review [31], the outcomes of 12 pre-
viously reported patients for whom follow-up informa-
tion was available were as follows: Death of disease (n =
8), alive with recurrences within 2 years (n = 2), and alive
after 5 years, disease status unstated (n = 2). In the largest
series of 8 patients reported by Abell and Ramirez [9], 4 of
the 6 patients that died did so of distant, hematogeneous
metastases.
2. Malignant Peripheral Nerve Sheath Tumor
Malignant peripheral nerve sheath tumors (MPNST), also
reported as "malignant schwannoma", "neurogenic sar-
coma" and "neurofibrosarcoma", encompass any malig-
nant tumor that shows differentiation "towards cells
which are intrinsic to the peripheral nerve sheath" [32].
Eight cases of MPNST have been reported [33-38]. The 8
patients ranged in age from 25 to 73 years (mean 50
years). No predilection for patients with either of the neu-
rofibromatosis syndromes was evident from a review of
the reported cases. In contrast to leiomyosarcomas, the
tumors in the reported cases of MPNST were generally
smaller, presenting as polypoid masses measuring 3 to 4
cm. In general, the malignant nature of these tumors were
evident upon their microscopic inspection, as they were
comprised of an infiltrative and cellular proliferation of
atypical, mitotically active spindle cells. The diagnostic
dilemma is likely to arise from the failure to recognize
their nerve sheath differentiation [4]. Subtle morphologic
clues are present, however, which should cause one to
include the appropriate markers in an immunohisto-
chemical panel investigating an apparent cervical spindle
cell sarcoma. The spindle cells may be arranged in herring-
bone, nodular or storiform fascicles [35-38]. In contrast to
other sarcomas, the cells of MPNST tend to infiltrate but
not destroy the native endocervical glands [36]. Occasion-
ally, alternating hypocellular areas that may be myxoid,
fibrous or edematous may be encountered [36]. Morpho-
logic variations that have been reported include epithe-
lioid areas in at least 2 cases [34,36], and pigmentation in
one case [38]. Application of a judicious immunohisto-
chemical panel is useful, especially in the distinction of
cervical MPNST from leiomyosarcomas, as the former
tumors are generally positive for S100 and vimentin and
are negative for desmin, myoglobin and actin [36]. How-
ever, as is well-known, MPNST at all anatomic locations
may display minimal to no immunoreactivity for S100.
Meaningful follow-up information is only present in 4
(50%) of the 8 reported cases: 3 patients were alive with-
out disease at 1–2 years follow-up [33,35,38], whereas the
4th developed abdominal metastases approximately 1.7
years after initial treatment [36].
3. Ewing Sarcoma (Primitive Neuroectodermal Tumor)
Ewing sarcoma (primitive neuroectodermal tumor, EW/
PNET), a primitive round cell sarcoma showing varying
degrees of neuroectodermal differentiation [39], has
rarely been reported in the uterine cervix. Nine previously
reported cases of primary PNET of the cervix were
retrieved in the current literature survey [40-47]. In con-
trast to osseous EW/PNET, in which the affected patients
are generally less than 20 years old [39], the reported
patients with cervical EW/PNET ranged in age from 21 to
51 years (mean 38 years). As with the aforementioned sar-
comas, most of these patients present with abnormal vag-
inal bleeding. Preoperative radiographic analysis will
generally show a well-circumscribed mass of approxi-
mately 5–7 cm, which caused its misinterpretation as a
cervical leiomyoma in at least 2 cases [41,44]. Fadare et al
[4] have previously summarized the outcomes in these 9
patients: Six of the 7 patients who presented with local-
ized disease were alive without evidence of recurrent or
metastatic disease at an average follow-up of 19 months
(range 5–42 months). The seventh patient died 4.2 years
after initial assessment with pulmonary metastases [46].
Initial management modalities for this group of 7
included various combinations of surgical resection, adju-
vant or neoadjuvant chemotherapy [40,41,43,47] (with
radiotherapy in 2 cases [45,46]). In two patients, the
tumors were considered non-resectable [41,44]. For both
patients, hysterectomies were preceded by neoadjuvant
chemotherapy. One patient reportedly "achieved full
remission" [41]. Follow-up information was not given in
the other (44). Snijders-Keilholz et al [40] have recently
advocated that the management approach to cervical EW/
PNET be similar to their osseous counterparts: induction
chemotherapy, surgery, and consolidation chemotherapy
[40].
4. Alveolar Soft Part Sarcoma
Alveolar soft part sarcoma (ASPS), a tumor of uncertain
differentiation, is comprised of a uniform population of
large cells with eosinophilic to granular cytoplasm which
are arranged in solid and/or alveolar nests [48]. As we
have previously noted [4], in the gynecologic tract, ASPS
apparently has a predilection for the cervix, as cervical
cases comprise 11(38%) of the 29 cases that have been
reported in this system [49-57]. The 11 patients with cer-
vical ASPS ranged in age from 8 to 39 years (mean 29.9).
In this respect, cervical ASPS are similar to their counter-
parts arising from the soft tissues, which most commonly
occur in patients between 15 and 35 years [48]. However,
some noteworthy differences exist between the tumors
arising from these 2 locations (vide infra). In two of the 11Diagnostic Pathology 2006, 1:30 http://www.diagnosticpathology.org/content/1/1/30
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patients, their tumors were incidental discoveries during
the examination of their uteri, which were resected for
unrelated reasons. However, most patients (8 of the
remaining 9) presented with abnormal vaginal bleeding
or menstrual cramping [49-56]. Macroscopically ASPS are
generally well-circumscribed (in contrast to their soft tis-
sue counterparts), with tan to yellow cut surfaces and foci
of hemorrhagic degeneration [50]. The 11 tumors ranged
in size from 2 mm to 4 cm (mean 2.35 cm). [4]. Micro-
scopically, cervical ASPS display the same distinctive mor-
phologic features of their soft tissue counterparts.
Notably, alveolar areas may be minimal and solid areas
may predominate [50]. As shown in the series of Nielsen
et al [50], mitotic activity is generally low and there
should be no more than moderate nuclear atypia in cervi-
cal ASPS.
The propensity for soft tissue ASPS to show early metas-
tases, especially to the thoracic and cranial cavities, is well-
known [48]. No such propensity was identified based on
the author's review of these 11 cases. However, it should
also be noted that standard staging procedures were not
performed for most of these cases. In one noteworthy case
in which staging procedures were performed, a focus of
metastatic tumor was present in an obturator node, even
though no residual tumor was identified in the cervix fol-
lowing the initial biopsy diagnosis [57].
Overall, follow-up was available in all but 1 [49] case. In
8 (80%) of these 10 cases, there was no evidence of tumor
metastases or recurrence with an average follow-up of 48
months (range 9–192). In the aforementioned case with
an obturator lymph node metastasis [57], follow-up was
largely unremarkable. Another patient experienced multi-
ple recurrences of her tumor after initial treatments with
cryotherapy prior to definitive diagnosis and treatment
(hysterectomy) [54]. Most (82%) of the 11 patients were
treated with a surgical intervention that included at least a
hysterectomy. One patient received only radiotherapy
after her initial biopsy [52] while another only received
chemotherapy after an initial excision [50].
Although only a few cases of cervical ASPS have been
reported, it is noteworthy that there have been no exam-
ples of pulmonary or brain metastases or death from dis-
ease. Cervical ASPS may have a better prognosis than soft
tissue ASPS, although more cases are required to establish
this possibility.
5. Undifferentiated Endocervical Sarcoma
Occasionally, sarcomas that show no specific line of dif-
ferentiation at the light microscopic level are encountered
in the cervix. Most of these tumors were reported prior to
the routine use of immunohistochemistry, therefore it is
probable that they are histogenetically heterogeneous.
Abell and Ramirez [9], as well as Clement [58], have
referred to these tumors as endocervical stromal sarcoma. In
the current classification from the World Health Organi-
zation, however, they are designated undifferentiated
endocervical sarcoma [59]. Seventeen examples of these
cases have been reported [3,9,20,60,61] in patients rang-
ing in age from 29 to 72 years (mean 51). As with most of
the aforementioned sarcomas, the patients most com-
monly came to clinical attention due to abnormal vaginal
bleeding. Their clinical appearances have been quite vari-
able, ranging from protruding polypoid masses, ulcerated
cervical masses or circumferential replacement of the cer-
vix [9]. Indeed, in some patients, the tumors had such a
non-descript appearance as to be initially misinterpreted
as benign polyps [4]. The microscopic appearance of
undifferentiated endocervical sarcoma is that of a moder-
ate to high-grade, undifferentiated sarcoma. The constitu-
ent cells are stellate to spindle and are composed of
moderately pleomorphic, hyperchromatic nuclei with
minimal cytoplasm. Architecturally, the cells are config-
ured in a sheet-like, storiform or fascicular pattern [9].
Mitotic figures are easily found, and finding greater than
10 mitotic figures per 10 high power fields in the most
active areas of the tumor is typical [9,20,61,62]. Other
findings in most cases include hemorrhage, necrosis, and
stromal edema [9]. In one case [61], heterologous ele-
ments (cartilage) were identified.
The patient outcomes have been somewhat variable,
which may be a reflection of the aforementioned proba-
ble histogenetic variability of these tumors. However, it
may be stated that the outcomes for these patients have
been generally unfavorable. Of the 14 patients with fol-
low-up information, 4 patients were alive with no evi-
dence of tumor recurrence or metastases at an average of
8 years after their diagnoses (range 2–18). Seven patients
died of their disease within 2 years of their diagnoses. The
three remaining patients showed evidence of either tumor
recurrence or metastases: one patient developed 2 vaginal
relapses both of which were excised, and she had no evi-
dence of disease at 11 years of further follow-up [9]. Two
patients showed radiographic evidence of pulmonary
metastases 7–18 months after their initial evaluations.
One of these patients [20] was lost to follow-up. In the
other, the metastatic lesion was resected, and she was alive
without evidence of disease after 7 years of additional fol-
low-up.
6. Liposarcoma
Lipomatous tumors, whether benign or malignant, are
extraordinarily rare in the uterine cervix [4]. The 1955
review of Bradfass et al [62] remains the definitive sum-
mary on the occurrence of lipomatous tumors in the
uterus. These tumors may arise from the misplacement of
an embryonic progenitor cell, metaplasia of mature mes-Diagnostic Pathology 2006, 1:30 http://www.diagnosticpathology.org/content/1/1/30
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enchymal tissues of other types, perivascular adipocytes or
from traumatic displacement of adipocytes [62]. As one
may anticipate, benign lipomas significantly outnumber
liposarcomas at this location [4]. Indeed, to the author's
knowledge, only four cases of pure liposarcoma of the cer-
vix have been reported in the English literature [63-66].
The 4 patients had an average age of 54 years (range 45–
62). Their tumors were generally large, with 3 of the 4
cases being ≥ 9 cm. Clinically and macroscopically, they
formed protruberant polypoid masses with areas of gross
hemorrhage. No histologic variant was predominant
amongst the 4 cases: 2 were pleomorphic [63,65], 1 was
round cell [66] and 1 was well-differentiated [64]. As
expected, the 2 cases of pleomorphic liposarcoma [63,65]
both recurred within a year after their primary resections.
Follow up was information was unavailable in the 3rd case
and was unremarkable in the 4th.
Summary and Conclusion
Cervical sarcomas constitute less than 1% of all cervical
malignancies. With the exception of rhabdomyosarco-
mas, which have been well-characterized (4), the most
commonly reported cervical sarcomas are reviewed
herein. Each of these entities appear to have a distinctive
clinicopathologic profile. Management options should be
based on the outcomes of the previously reported exam-
ples of the entity in question. Indiscriminate direct extrap-
olations from their soft tissue counterparts may not be
appropriate, at least for all entities.
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